Xihua People's Hospital
Welcome,         Profile    Billing    Logout  
 5 Trials 
7 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
He, Yong
NCT05437900: INSIGHTFUL-FFR Clinical Trial

Recruiting
4
2500
Europe, RoW
Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care
CoreAalst BV, Insight Lifetech Co., Ltd.
Coronary Artery Disease, Acute Coronary Syndrome
06/26
06/30
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial

Hourglass Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity
Completed
3
731
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
07/24
07/24
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting
3
110
RoW
68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET
Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
12/25
07/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT06032572: Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)

Not yet recruiting
N/A
204
RoW
VRS100 robotic-assisted PCI, Manual PCI
Shenzhen Raysight Intelligent Medical Technology Co., Ltd., Shanghai Zhongshan Hospital, West China Hospital, Shenzhen People's Hospital
Coronary Artery Disease, Cardiovascular Diseases, Coronary Disease, Myocardial Ischemia, Arteriosclerosis, Vascular Disease Occlusive
08/24
08/24
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
Li, Chaoqun
No trials found

Download Options